Human leukocyte antigen genotype modulates cytomegalovirus- and Epstein–Barr virus-specific T-cell response in healthy donors for optimized virus-specific T-cell donor selection
Frontiers in Immunology · 14.08.2026 · 17
DOI: 10.3389/fimmu.2026.1856550 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 14.08.2026. Verfasst von Rut Mora-Buch und 7 weiteren Autor:innen. Beteiligte Einrichtung: Advanced & Cell Therapy Services, Blood and Tissue Bank (BST), Barcelona, Spain. Hauptthemen laut MEDLINE: Herpesvirus 4, Human, Cytomegalovirus, HLA Antigens, Epstein-Barr Virus Infections. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Reactivation of cytomegalovirus (CMV) and Epstein–Barr virus (EBV) is a major complication in immunocompromised patients, and understanding donor variability in antiviral immunity is essential for optimizing adoptive T-cell therapy. This study aimed to identify immunogenetic determinants of virus-specific T-cell responses in healthy donors to guide donor selection.
Methods
CMV- and EBV-specific T-cell responses were characterized using flow cytometry and IFN-g ELISpot after stimulation with peptide pools, followed by integrated analyses correlating the response magnitude with human leukocyte antigen (HLA) class I and II alleles, HLA haplotypes, and HLA-G 3′UTR polymorphisms.
Results
CMV 65-kDa phosphoprotein (pp65) induced stronger CD8 + and CD4 + T-cell responses than immediate early 1 (IE1), whereas the EBV consensus peptides preferentially activated CD8 + T cells. Several HLA alleles and linked haplotypic backgrounds were associated with enhanced or reduced CMV-specific T-cell responses, including an A*01:01~C*07:01~B*08:01~DRB1*03:01~DQB1*02:01 haplotype enriched among low responders. For EBV, several HLA-restricted alleles were associated with stronger peptide-specific activation, supporting the broad immunogenicity of the consensus peptide pool. Moreover, HLA-G 3′UTR polymorphisms selectively modulated the CMV-specific IFN-γ + CD8 + T-cell frequencies.
Discussion
Together, these results indicate that classical and non-classical HLA variations are associated with inter-donor differences in antiviral T-cell response in an antigen- and virus-dependent manner, providing a translational framework to refine donor selection and improve the design of T-cell-based immunotherapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Advanced & Cell Therapy Services, Blood and Tissue Bank (BST), Barcelona, Spain.
- Transfusional Medicine Group, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona (VHIR-UAB), Barcelona, Spain.
- Immunogenetics and Histocompatibility Laboratory, Blood and Tissue Bank (BST), Barcelona, Spain.
- Barcelona Supercomputing Center, Barcelona, Spain.
Zitieren
APA
Mora-Buch, R., Pasamar, H., Tomás-Marín, M., Enrich, E., Andrés-Rozas, M., Peña-Gómez, C., García Bosca, M., & Rudilla, F. (2026). Human leukocyte antigen genotype modulates cytomegalovirus- and Epstein–Barr virus-specific T-cell response in healthy donors for optimized virus-specific T-cell donor selection. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1856550
Vancouver
Mora-Buch R, Pasamar H, Tomás-Marín M, Enrich E, Andrés-Rozas M, Peña-Gómez C, et al. Human leukocyte antigen genotype modulates cytomegalovirus- and Epstein–Barr virus-specific T-cell response in healthy donors for optimized virus-specific T-cell donor selection. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1856550
BibTeX
@article{MoraBuch2026,
author = {Mora-Buch, Rut and Pasamar, Helena and Tomás-Marín, Maria and Enrich, Emma and Andrés-Rozas, María and Peña-Gómez, Cleofé and García Bosca, Miriam and Rudilla, Francesc},
title = {Human leukocyte antigen genotype modulates cytomegalovirus- and Epstein–Barr virus-specific T-cell response in healthy donors for optimized virus-specific T-cell donor selection},
journal = {Frontiers in Immunology},
year = {2026},
volume = {17},
doi = {10.3389/fimmu.2026.1856550}
}
EUVIMED